Evexomostat Plus Alpelisib and Fulvestrant in Women With the PIK3CA Mutation With HR+/Her2- Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HR+/HER2-negative Breast Cancer|Metastatic Breast Cancer
Interventions: DRUG: Evexomostat
Sponsor: SynDevRx, Inc.